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In comparison to conventional αβT cells, γδT cells are considered as specialized T cells
based on their contributions in regulating immune response. γδT cells sense early envi-
ronmental signals and initiate local immune-surveillance. The development of functional
subtypes of γδT cells takes place in the thymus but they also exhibit plasticity in response
to the activating signals and cytokines encountered in the extrathymic region. Thymic
development of Tγδ1 requires strong TCR, CD27, and Skint-1 signals. However, differen-
tiation of IL17-producing γδT cells (Tγδ17) is independent of Skint-1 or CD27 but requires
notch signaling along with IL6 and TGFβ cytokines in the presence of weak TCR signal.
In response to cytokines like IL23, IL6, and IL1β, Tγδ17 outshine Th17 cells for early acti-
vation and IL17 secretion. Despite expressing similar repertoire of lineage transcriptional
factors, cytokines, and chemokine receptors, Tγδ17 cells differ from Th17 in spatial and
temporal fashion. There are compelling reasons to consider significant role of Tγδ17 cells
in regulating inflammation and thereby disease outcome.Tγδ17 cells regulate mobilization
of innate immune cells and induce keratinocytes to secrete anti-microbial peptides thus
exhibiting protective functions in anti-microbial immunity. In contrast, dysregulated Tγδ17
cells inhibit Treg cells, exacerbate autoimmunity, and are also known to support carcino-
genesis by enhancing angiogenesis. The mechanism associated with this dual behavior of
Tγδ17 is not clear. To exploit, Tγδ17 cells for beneficial use requires comprehensive analy-
sis of their biology. Here, we summarize the current understanding on the characteristics,
development, and functions of Tγδ17 cells in various pathological scenarios.
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INTRODUCTION
Decades have passed since the accidental discovery of T cells
expressing γ and δ chains (1), yet it is hard to define γδT cells like
αβT cells. Ambiguity in understanding the functions of γδT cells is
attributed to their unparalleled characteristics as compared to αβT
cells. Current understanding of T cell biology has emerged exten-
sively from studies on αβT cells; however, recent findings have
underlined the crucial role of γδT cells in shaping the immune
response in infections, inflammatory diseases, and cancer. They
are involved in early immune response like innate cells, produce
proinflammatory cytokines (IFNγ, IL17, and TNFα), and acti-
vate adaptive immune cells. The cytokines secreted by γδT cells
determine their effector functions. In humans, the major cytokine
produced by γδT cells is IFNγ, contributing to its role in anti-
viral, anti-bacterial, and anti-tumor immunity (2–4). However,
upon activation γδT cells can be skewed toward IL17, IL4, or
TGFβ producing phenotype governed by the polarizing cytokines
present in the surrounding milieu (5). Recent investigations in
mice and human have highlighted the role of IL17-producing γδT
cells (hereafter referred as Tγδ17) in bacterial infection, inflam-
matory disease, and cancer (6–8). They are the primary source of
IL17 in early disease condition and are pivotal in progression and
disease outcome (9, 10). To understand the functional significance
of Tγδ17 in pathological conditions, many efforts have made in
mouse models but there is scanty literature available on human
Tγδ17 cells. In this review, we will discuss the recent findings of
Tγδ17 differentiation, mechanisms regulating IL17 production,
and their relevance in pathological conditions.
γδT CELLS: UNIQUE BUT VERSATILE
Survival of γδT cells over strong evolutionary selection pressure
highlights their exclusive importance and disparate properties
from conventional αβT cells. Initially, γδT cells were considered
as cells of innate immunity owing to their ability to recognize
conserved non-peptide antigens expressed by stressed cells. In
addition to this, they recognize pathogen-associated molecular
pattern (PAMP) or danger-associated molecular pattern (DAMP)
through pattern recognition receptors (PRR) expressed by them
(11). Like adaptive immune cells, human γδT cells undergo clonal
expansion and exhibit antigen-specific memory (12). Thus, γδT
cells link innate and adaptive immunity thereby enhancing the
immune response against invading pathogen or danger signal
posed by “self” cells. Antigen recognition by murine or human
γδT cells does not require antigen presentation by major his-
tocompatibility complex (MHC) class I or class II (13) and the
crystal structure of γδTCR has revealed its close homology with
immunoglobulins suggesting that antigen recognition by γδT cells
is similar to antigen–antibody interaction (14). However, diversity
of antigens recognized by γδT cells brands it different from B cells.
The antigens exclusively recognized by γδT cells are not peptides
of protein antigens rather are small mono- and pyrophosphates
of linear C5 isoprenoids called as phosphoantigens (13). These
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prenyl pyrophospahtes are metabolites of cholesterol biosynthesis
and are recognized through complementarity determining regions
(CDRs) of γδT cells (15). In humans,during cholesterol biosynthe-
sis, phosphorylated precursors such as isopentenyl pyrophosphate
(IPP) and DMAPP (dimethylallyl pyrophosphate) are synthe-
sized by mevalonate pathway (16). However, microbial pathogens
use non-mevalonate pathway to produce these phosphorylated
precursors (17). γδT cells respond to these natural or synthetic
stimulators with varying degree. Based on this, stimulators are
classified either as weak or potent stimulators. HMBPP [(E)-
4-hydroxy-3-methyl-but-2-enyl pyrophosphate], a metabolite of
non-mevalonate pathway of bacteria Mycobacterium tuberculosis
is 104 times more potent stimulator of human γδT cells than
IPP (18). The exclusive response of γδT cells to these phospho-
antigens has a potential therapeutic significance and synthetic
pyrophosphates can be used to harness the cytotoxic potential
of γδT cells.
Murine and human γδT cells also recognize phycoerythrin
(PE) – fluorescent molecule of cyanobacteria and red algae. PE is
directly recognized by γδT cells but there is no sequence similarity
between PE-specific murine and human γδ TCR (19). Naturally
occurring primary alkyl amines activate human Vγ2Vδ2 T cells
and enhance immunity against certain microbes and plant-derived
antigens (20, 21). Similar to natural killer (NK) cells, human
γδT cells also recognize the stress-induced MHC class I-related
molecules MICA, MICB, and the UL16-binding proteins that are
upregulated on malignant or stressed cells (22, 23). The stress-
related molecules are ligands for NKG2D expressed by γδT cells
and this engagement also enhances γδT cells’ response to non-
peptide antigens (24). Human and murine γδT cells recognize
lipid antigens presented by CD1 molecules, a classical ligand for
NK T cell suggesting the phenomenon similar to MHC-restricted
antigen recognition by αβT cells (25–27). The murine γδT cells
also recognize non-classical MHC class I molecules like T10 and
T22 (β2 microglobulin-associated molecules lacking peptide bind-
ing groove) (28, 29). In addition to non-protein and MHC related
antigens, murine and human γδT cells also recognize small pep-
tides such as heat shock proteins (HSPs) (30–32). However, they
do not require antigen-presenting cells (APCs) and recognition of
antigen is MHC unrestricted, resembling B cells (33). Thus, the
broad spectrum antigen responsiveness of γδT cells helps them to
mount faster immune response.
Like αβT cells, γδT cells develop in the thymus from
CD4−CD8− (double negative, DN) thymocytes (34); however,
they precede αβT cells in T cells ontogeny. γδ TCR rearrange-
ments can be traced in early embryonic stages in mice as well as
in humans (35, 36). This highlights their role in neonatal protec-
tion as conventional T cells are functionally impaired and APCs
are immature in newborns (37). During thymic development, the
decision of γδ versus αβ T cell commitment is determined by
TCR signal strength or notch signaling (38). In mice, the strong
TCR signaling in absence of notch signal induces γδT cells lin-
eage commitment whereas low TCR signal strength in presence of
strong notch signaling promotes αβ T cell lineage (39–41). How-
ever, notch signaling alone is insufficient to decide γδ/αβ T cell
commitment. The intrinsic signals from T cell receptor complex
and trans-conditioning by different subsets of thymocytes also
determine thymic development of γδT cells (42). In humans,notch
has opposite role in αβ versus γδT cell lineage decision, sustained
notch signaling is required for the development of γδT cells (43)
which is determined by differential notch receptor–ligand interac-
tion importantly Jagged2/Notch3 signaling (44). In human, γδT
cells differentiate along two pathways, a notch-independent DN
pathway, generating mature DN and CD8αα+ SP (single posi-
tive) TCRγδ+ cells. In the notch-dependent DP (double positive)
pathway, immature CD4+ SP, and subsequently DP TCRγδ+ cells
are generated. Human postnatal thymus thus exhibits a scenario
of DN, DP, and SP TCRγδ+ population, which highlights het-
erogeneity in human γδT cell development (45). The activated
extrathymic γδT cells, in humans, express notch receptors, which
regulate their effector functions. Inhibiting notch signaling in γδT
cells dampened their anti-tumor cytotoxic potential (46). Thus,
validates the requirement of notch signaling in both thymic devel-
opment and functions of human γδT cells. The diversity of human
γδ T cell repertoire at birth (majorly contributed by Vδ1+ subset
of γδT cells in cord blood) is restricted in adulthood especially
to Vγ9Vδ2, a circulating subset of γδT cells. The absolute num-
bers of Vγ9Vδ2 T cells increase from minor population at birth to
more than 75% of γδT cells pool in peripheral blood (35), which
constitute around 1–10% of total T cells in humans. The γδT cells
exit the thymus as mature T cells and express markers that are
associated with antigen-experienced T cells (47).
The other important feature of γδT cells apart from antigen
recognition is their tissue tropism. In humans, the first γδT cells
to arise from thymus are Vδ1+ (paired with various Vγ chains),
which preferentially populate in epithelial tissue and constitute
larger proportion of intraepithelial lymphocytes (IELs) (48). They
rapidly and innately recognize stressed cells found to be enriched
in various tumor tissues (4). The Vγ9Vδ2 is a lymphoid hom-
ing subset of γδT cells, which continually expand in response
to microbial antigen in circulation and exhibit characteristics of
adaptive immune system (49). These cells recognize, expand, and
secrete cytokines in response to non-peptide antigens associated
with microbes in circulation. In mouse, a substantial proportion of
γδT cells reside as the IEL in the skin, intestine, and genitourinary
tract. In response to the chemokine signals, Vγ5Vδ1+ T cells leave
the fetal thymus, reside in the epidermis, and form dendritic-like
network similar to Langerhans cells. These cells are called as den-
dritic epidermal T cells (DETCs) and constitute more than 90% of
epidermal T cells (50). Vγ6+ T cells home to tongue and reproduc-
tive tract whereas Vγ7+ T cells home to intestinal tract suggesting
that distinct TCR repertoire are present at different anatomical site
and respond to antigens unique to their resident tissues (51–53).
However, the functions of IELs are determined by the environ-
ment at the anatomical site (54) and hence specific γδ T cell subset
could be used in tissue repair and generation of effective immune
response at different epithelial sites.
γδT cells perform diverse effector functions determined by the
TCR expressed, tissue localization, and activation status. Apart
from these, MHC-independent recognition of antigens, produc-
tion of IFNγ, and expression of cytotoxic granules classify γδT
cells as potential cytotoxic cells (55). They can kill activated,
infected, stressed, and transformed cells using various strategies
such as engagement of death-inducing receptors, such as FAS
Frontiers in Immunology | T Cell Biology February 2015 | Volume 6 | Article 37 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patil et al. Tγδ17 in infection and inflammation
and TNF-related apoptosis-inducing ligand receptors (TRAILR)
and the release of cytotoxic effector molecules such as perforin
and granzyme (56, 57). Human γδT cells also recognize HSP
(HSP60/70) expressed on tumor cells and enhance its cytolytic
activity against the tumors (31, 58). γδT cells support the mat-
uration and activation of other lymphocytes, NK cells, and
macrophages with the help of secreted chemokines (CCL3, CCL4,
CXCL10) (55). Another chemokine CXC–chemokine ligand 13
(CXCL13) produced by Vγ9Vδ2 cells can regulate B cell organiza-
tion within lymphoid tissues and help B cells to produce antibodies
(59). Human γδT cells can also crosstalk with dendritic cells (DCs)
influencing each other functions like the antigen presentation by
DCs, activation, and secretion of IL12 and IFNγbyγδT cells, which
result in DC maturation (11, 60). These properties of γδT cells aid
in generation of the effective immune response in the appropriate
condition. Not only this, activated Vγ9Vδ2 cells can take up and
process the soluble antigens, opsonize target cells, and can migrate
to lymph nodes through CC-chemokine receptor 7 (CCR7) where
they upregulate expression of MHCs and co-stimulatory recep-
tors CD80 and CD86 (61, 62). Activated Vγ9Vδ2 cells has also
been licensed to act as APC and activate CD4 and CD8 T cells
(63). Collectively, these observations highlight the multi-talented
role of γδT cells, having both Th- and Tc-like properties along with
acting as APC. The special trait of γδT cells is their ability to recog-
nize phosphorylated non-protein antigens and mediate its effector
function in spatial and temporal manner making them a robust
cell type, which can be manipulated to develop a promising tool for
novel immunotherapies against certain types of diseases. However,
care should be adapted while designing such immunotherapies
because these cells have capacity to secrete various cytokines under
different conditions.
Tγδ17: A SUBTYPE OF γδ T CELLS
Unlike αβ T cells, in mice, which leave thymus as naïve cells and
are primed in the peripheral compartment,γδT cells undergo sub-
set commitment in the thymus itself. However, in humans, upon
activation with different cytokines, Vγ9Vδ2 cells can be polarized
toward different effector subtypes like γδ1,γδ2 (64),γδ17 (65, 66),
and γδTreg (67, 68). This functional plasticity of γδT cells assists
them to tackle the distinct disease conditions and play impor-
tant role in the early responses to invasive pathogens. The recent
findings have stated that γδT cells are major IL17 producers and
have shown their involvement in early onset of immune activa-
tion (69). Similar to Th17 cells, Tγδ17 cell express RORγt as a
lineage determination transcriptional factor (70). Healthy adult
human peripheral blood Vγ9Vδ2 T cells distinctively express Th1
signature and 50–80% produce IFNγ but <5% produce IL17 (6).
However, Tγδ17cells have been demonstrated to be involved in
the pathogenesis of transplantation rejection (71), autoimmune
disease (72), allergy (73), and cancer (74) in humans. The biology
of Tγδ17 is so naive that it compels us to cross-examine its gene-
sis, functions, and clinical relevance to understand its therapeutic
potential.
MOLECULAR EVIDENCES OF Tγδ17 GENESIS
The molecular mechanism of IL17-producing γδT cells remains
an enigma. Most of the studies carried out to understand the
differentiation mechanisms of Tγδ17cells are based on the murine
models. γδT cells preferentially localized to barrier tissues are the
initial source of IL17 and are likely to originate from the fetal
thymus. These are called as the natural IL17-secreting γδT cells.
γδT cells that make IL17 within 24 h fall in this category (75). γδT
cells acquire IL17-secreting phenotype in secondary lymphoid tis-
sues after antigen exposure, which is referred to as induced Tγδ17
cells (76, 77).
During development of T cells in thymus, murine γδT cells
branch off at the transition of thymocytes from DN3 stage to DN4
stage (34). It is also reported that γδT cells develop from DN2 stage
and specifically produce IL17 whereas IFNγ-producing γδT cells
can develop from both DN2 and DN3 precursors (78) (Figure 1).
This suggests that γδT cells do not develop like αβT cells and fol-
low evolutionary ancient path of T cell development. However,
the precise DN stage from which γδT cells develop is elusive (79).
Fetal thymic γδ T-cell development occurs in successive waves by
using the different Vγ and Vδ segments during the embryonic
development (34, 80). Successful gene rearrangement of γδ T cells
from early thymic precursors (CD44hi) lead to the development
of naïve γδ T cell characterized by CD44lo CD27+CD62L+ phe-
notype. This phenotype can either leave the thymus to populate in
secondary lymphoid organs or it can undergo further intrathymic
differentiation that results in the development of multiple γδT cell
subtypes such as dendritic epidermal γδT cell (DETCs), Tγδ17, or
NK 1.1+ γδ cell (γδNKT cells) (80, 81). Recently, it was described
that when thymic lobes of mice at E14 were colonized with DN1a
cells from mice at E13 and E18, respectively. It was observed that
although both populations (E13 DN1a cells and E18 DN1a cells)
generated similar number of γδT cells, only E13 DN1a cells gen-
erated Vγ3+ DETCs. These observations indicate that precursor
lineage of DETCs may be different and needs further investigation
(82). DETCs develop at embryonic day 13 (E13) to approximately
E17 and readily secrete IFNγ when activated. After the develop-
ment of DETCs, the next functional developmental wave consists
of Tγδ17 cells. Tγδ17 cells are heterogeneous in using TCR chains
that mainly include Vγ6+ and Vγ4+ but also use Vγ1+ chain.
Vγ6+ cells develop by E14 to around birth and finally Vγ1 and
Vγ4 cells develop E16 onward (81). The other subtypes of γδ T
cells, which develop in thymus, are γδ NKT cells, which are similar
to invariant TCRαβ+ NKT cells (83, 84).
There are different thymic signaling processes, which determine
functional phenotype of γδT cells in thymus before migration to
periphery and contribute to the balance between IFNγ committed
versus IL17-commited subtypes (85). This biasness toward IL17
or IFNγ depends on the antigen experience in thymus. The γδ T
cells that have encountered the cognate antigen interaction in thy-
mus, gain the potential to differentiate into the IFNγ-producing
functional phenotype while antigen naïve γδ T cells develop into
IL17-producing γδT cells (86). This skewedness also reflects in
their distribution outside the thymus. Most of Tγδ17 cells reside in
lymph nodes whereas IFNγ-producing γδT cells are mainly found
in the spleen and the mechanism for this distribution is not clear
(86). Similar distribution is also found in αβT cells and it seems to
be logical as the lymph nodes serve as the site of initial exposure
to foreign antigens and propagate the wave of inflammation, thus
are suited for the earliest source of the IL17 secretion (87).
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FIGURE 1 | Overview ofTγδ17 cells development. The figure illustrates the
differentiation of Tγδ17 cells from T cell progenitors in the murine thymus
(A–C) and from naïve γδT cells in periphery in human (D). Progenitor T cells
differentiate through double negative stage 1 (DN1) to DN stage 4 (A). The
decision of αβ or γδTCR expression takes place at early T cells precursor
(from DN2 or DN3 stage) as showed by dashed line. The thymocytes
expressing αβTCR develop into double-positive thymocytes, which support
differentiation of functional subtypes of γδT cells called as transconditioning.
DP thymocytes secrete LTβL, which support differentiation of Tγδ17. The DP
αβ thymocytes then exit the thymus as mature single positive T cells (either
CD4+ or CD8+ T cells) (A). The functional programing of γδT cells is
determined by TCR signal and/or other related signals. TCR signal, interaction
with Skint-1 from epithelial cells, downregulation of SOX13, and signaling
through CD27/CD70 divert γδ thymocytes toward IFNγ-producing phenotype
(Tγδ1), which migrate to periphery (B). Conversely, signaling through Notch
receptor maintain Sox13 levels with increase in Hes1 and RORγt expression
induce γδ thymocytes to produce IL17. Progression of γδ thymocytes to Tγδ17
cells is independent of signaling through Skint-1 and/or CD27 but require
inputs from IL6 and TGFβ. The natural Tγδ17 cells developed in thymus
migrate to tissue or periphery (C). In human, naïve γδT cells, which exit
thymus, can also differentiate into Tγδ17 cells in presence of TCR signal and
cytokines such as IL6, IL1β, IL23, and TGFβ (D).
Besides the γδTCR signaling (86), expression of tumor necrosis
factor receptor family member, CD27, determines the IL17 versus
IFNγ production by γδT cells (88). CD27+ γδT cells differentiate
into IFNγ producing cells whereas IL17 production was restricted
to CD27− T cells (89) (Figure 1). Thus thymic “imprinting” of
the γδT cells as CD27+ or CD27− regulates effector functions of
γδT cells and is preserved in the periphery (89). CD27 is not only
associated with IFNγ production but also aids γδT cells to interact
with its ligand CD70 expressed on DCs, thymic epithelial cells, and
double-positive thymocytes thus acting as a costimulatory recep-
tor (89). Therefore, CD27 conveys an intrathymic message that
licenses the CD27+ γδ T cells for the production of IFNγ (47).
Another signaling pathway that influences the differentiation of
Tγδ17 is the signaling through lymphotoxin-β receptor (LTβR), a
member of the tumor necrosis factor receptor family (90). Signal-
ing through LTβR leads to the activation of the alternative nuclear
factor (NF)-κB pathway via RelB. Ligands for LTβR regulating this
developmental process are produced by CD4+CD8+ thymocytes
(91). The homeostasis of this functional phenotypic differentia-
tion, influenced by other thymic progenitors is known as transcon-
ditioning (91), which highlights coordination between different
signaling pathways in thymus that occur in physically separate
thymic niche (92). LTβR signaling pathway controls Tγδ17 devel-
opment by regulating transcription factors RORγt and RORα4,
required for IL17 expression in γδ thymocytes (93). The role of
LTβR signaling, however, remains controversial as LTβR is present
downstream to CD27 signaling, which is associated with the IFN-γ
production (89).
The maturation of Tγδ17 cells from its precursors requires TCR
signaling as mice with reduced ZAP70 show decreased number
of Tγδ17 cells (94). However, TCR signaling alone is not suffi-
cient as it also requires other signals (95). An src family kinase,
Blk (B lymphoid kinase), is required for Tγδ17 cells development
in thymus as Blk-deficient mice was reported to have less num-
ber of IL17-producing γδ T cells (96). Similarly, high-mobility
group (HMG) box transcription factors, SOX4 and SOX13 are
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positive regulators of Tγδ17 development (95, 97). These tran-
scription factors expressed in immature T cells (98) highlight that
the development of Tγδ17 is from early precursors (DN2) (78, 95).
Other thymic determinant, which is responsible for the functional
dichotomy in Tγδ17 and Tγδ1, is Skint-1, a thymic epithelial cell
determinant. The interaction between Skint-1+ cells and γδ thy-
mocytes (Vγ5+Vδ1+) induce an Egr3-mediated pathway, leading
to differentiation toward IFNγ-producing γδ T cells. Further, it
suppresses Sox13 and an RORγt transcription factor-associated
Tγδ17 cells lineage differentiation suggesting that the functions of
the earliest T cells are substantially preprogramed in the thymus
(99). Notch signaling is known to be involved in thymic determi-
nation and development of Tγδ17 cells. Hes1, one of the basic
helix–loop–helix (bHLH) proteins induced by Notch signaling
is critical for the IL17 expression by γδ T cells and its thymic
development (100–102). Further, the specific expression of Hes1
in CD25+ and CD27− γδ T cells and decreased levels of Tγδ17
in Hes1-deficient mice highlights the critical role of Notch–Hes1
pathway in Tγδ17 development in thymus as well as in periph-
ery (101). The thymic development of Tγδ17 is independent of
STAT3 but partly dependent on RORγt (101) and most peripheral
IL17-producing γδ cells express RORγt and respond rapidly to
IL23 (103).
Developmental process of Tγδ17 also requires signaling
through different cytokines. TGFβ signaling is necessary for Tγδ17
development (104). It has been shown that in absence of TGFβ1
or Smad3 (a component of the TGFβ signaling), the number of
Tγδ17 thymocytes reduced drastically relative to that of wild-
type mice (104). As compared to TGFβ, requirement of IL6 for
Tγδ17 development is not well understood as there are contrast-
ing reports on its role (72, 105). It is also reported that IL6 does
not act directly on uncommitted γδ thymocytes but instead it acts
indirectly by regulating the expression of Delta-like ligand 4, a lig-
and for notch receptor, expressed by thymic epithelial cells that
promote the differentiation of Tγδ17 (101, 106). Moreover, IL23
and IL1 produced by DCs are crucial for IL17 production by γδT
cells. IL23−/− and IL23R−/− mice showed the significant reduc-
tion in Tγδ17 cells after L. monocytogenes infection supporting
earlier observation (107–110).
Thymic development of human Tγδ17 cells is poorly investi-
gated. Around 80% circulating human Vγ9Vδ2 T cells are IFN-γ
producers and express CD27 whereas CD27 negative cells are IL17-
producing γδ T cells are <5% (65). Interaction of CD70 with
CD27 promotes the expansion of Th1-biased Vγ9Vδ2 T cells in
periphery (111). However, such role in their thymic development
is unknown. HumanVγ9Vδ2 T cells can be polarized to Tγδ17 cells
in periphery upon IPP activation and in the presence of cytokines
like TGFβ, IL1β, IL6, and IL23, followed by a week of culture in
differentiation medium supplemented with IL2 can induce IL17
in these cells (65, 66). In humans, there are contrasting reports
on role of IL6 and IL23 in differentiation of Tγδ17. It has been
shown that IL6 is required for differentiation of neonatal Tγδ17,
and IL23 is required for the generation of adult IL17-producing
γδT cells (65). In another study, it is reported that in the pres-
ence of TCR signaling, IL23 promotes the induction of IL17 in
neonatal (but not adult) γδT cells (112). However, it appears that
IL23 induces γδT cells to coproduce IL17 and IFNγ in adults but
support development of Tγδ17 cells in neonates. In addition to the
above-mentioned cytokines, IL7 selectively promotes the mouse
and human IL17-producing γδT cells. IL7 activates STAT3 prefer-
entially in γδT cells competent to produce IL17 (113). However,
the increased IL17 production by γδT cells upon TCR stimulation
in presence of IL7 is observed only in case of cord blood cells but
not with peripheral lymphocytes. Thus, it is important to note
that the antigen naïve γδT cells only can be reprogramed in vitro
toward Tγδ17 phenotype (66, 113).
The kinetic study of IL17 production by γδT cells has shown
that murine γδT cells secrete IL17 within few hours after stim-
ulation (70). This phenomenon can be reasoned by the thymic
development of murine Tγδ17 cells and constitutive presence of
transcriptional regulators for IL17 production. However, human
γδT cells in thymus are functionally immature and can attain their
functional differentiation in periphery in presence of cytokines
(114). This supports the kinetics of IL17 production by human
γδT cells that mRNA expression of IL17 and RORγt peaks by day
3–6 and decrease by day 9 onward, after stimulation. The expres-
sion of cytokine receptors (IL1βR, IL6R, TGFβR, and IL23R) on
Vγ9Vδ2 T cells peaks on day 3 and decrease by day 6 (66). Thus,
coordinated combination of TCR and cytokine stimulation could
be necessary for the sustained secretion of IL17 by γδT cells, which
highlights the difference in kinetics of IL17 secretion by murine
and human Tγδ17 cells. This underscores that human γδ T cells
can be “reprogramed” in the periphery into different functional
lineages.
Upon antigenic challenge, T cells differentiate to memory phe-
notype; either central memory (TCM) or effector memory (TEM)
(115). Human Tγδ17 cells present in non-lymphoid environment
belong to CD27− CD45RA± effector (74) or terminally differ-
entiated (TEMRA) (66) memory phenotype. Similarly, murine
Tγδ17 cells also show effector memory phenotype with CD44high,
CD45RBlow, and CD62Llow (116). Thus, Tγδ17 cells differentiated
either in thymus or in periphery, belong to memory phenotype,
and licensed to patrol the blood, lymphoid organs, and peripheral
tissues.
Tγδ17 IN MICROBIAL INFECTIONS
Tγδ17 cells can rapidly produce IL17 upon Toll-like receptors
(TLR) or cytokine stimulation alone even in absence of anti-
gen presentation. The general proinflammatory functions of IL17
[reviewed in Ref. (117, 118)] could be associated with γδT cells
as they are major producers of IL17. Studies carried out in var-
ious infection models showed that Tγδ17 cells are protective
against infection. During mycobacterial infection, IL17 produced
by Vγ4+ and Vγ6+ cells induce pulmonary granuloma formation
by recruitment of granulocytes and monocytes. The IL17 par-
ticipates in maturation of granuloma by promoting tight cell to
cell binding via ICAM1 and LFA1 induction (119). Mycobacteria-
infected DCs secrete IL23, which regulate IL17 production by γδT
cells emphasizing that the early activation of Tγδ17 cells is impor-
tant for initiating inflammation and recruiting innate immune
cells to the site of infection thereby enhancing bacterial clear-
ance from host (120, 121). Tγδ17 cells also support cell-mediated
immunity by inducing Th1cells against pulmonary mycobacterial
infection (122).
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In Escherichia coli infection model also, γδT cells were reported
to be the major producers of IL17, which enhanced neutrophil
infiltration to the peritoneum. The infiltration of cells diminished
after antibody depletion of resident Vδ1+ subtype of γδT cells
highlighting its involvement in IL17 secretion in response to IL23
(9). Thus, IL23 and Tγδ17 cells play a dominant role as first line
of defense in infection before CD4 T cell activation. In case of L.
monocytogenes infection, a large number of γδ T cells accumulate
in the lymph organs shortly after infection and begin to produce
IL17A, signifying the role of Tγδ17 cells in the Listeria infection
(123). IL17 was also shown to promote proliferation of CD8+
cytotoxic T lymphocytes by enhancing DC cross-presentation
in vitro. DCs stimulated with IL17 showed upregulation of MHC-I
molecule H2Kb and enhanced secretion of cytokines (IL12, IL6,
and IL1β). CD8α+ DCs from Il17a−/− mice also produced less
IL12 and are less potent in activating naive CD8+ T cells (123).
This indicate that Tγδ17 cells not only induce innate response
but also critical for optimal adaptive cytotoxic response against
intracellular bacterial infection. The alliance of IL23 and Tγδ17
is also demonstrated to have a protective role during infections
such as Klebsiella pneumonia (124), Citrobacter rodentium (125,
126), Salmonella enterica (127, 128), and Toxoplasma gondii (129).
The Tγδ17 cells also play a vital role in clearing fungal infections.
The rapid production of IL17A was reported in the lungs at a
very early stage after intravenous infection with C. albicans. Lung
resident γδ T cells were the major source of early IL17A pro-
duction regulated by IL23 and TLR2/MyD88-dependent pathway
(130). Presence of Tγδ17 cells were also reported in the lungs of
neutropenic mice during C. neoformans infection. These Tγδ17
cells played an important role in the chemotaxis of leukocytes and
induction of protective immune response (131). Tγδ17 cells thus
orchestrate the protective immunity by acting at the early onset in
infection models (108).
Relatively few studies have evaluated the role of Tγδ17 cells in
human microbial immunity. In patients with tuberculosis (TB),
elevated levels of Tγδ17 cells were found in peripheral blood and
were major producers of IL17 (6). As a protective role, in response
to bacterial antigens, IL17-producing Vγ9Vδ2 T cells induce neu-
trophil migration through secretion of CXCL8 and promote their
phagocytic activity (66). Tγδ17 cells also induce epithelial cells to
secrete anti-microbial peptides like β-defensins in response to bac-
terial antigens (66). This signifies the modulatory effects of Tγδ17
cells on keratinocytes and other immune cells in anti-microbial
defense. In children with bacterial meningitis, the population of
IL17+ Vγ9Vδ2 T cells significantly increase in peripheral blood
and at the site of infection (cerebrospinal fluid). The reversal of
this pattern after successful anti-bacterial therapy clearly suggests
the anti-microbial role of Tγδ17 cells (66). Collectively, these stud-
ies provide new insight into the functions of γδ T cells as the first
line of host defense against bacterial and fungal infection in human
and may pave a path in designing newer treatment modalities.
TOLL-LIKE RECEPTORS REGULATE IL17 PRODUCTION IN
Tγδ17 CELLS
γδT cells express various chemokine receptors, cytokine receptors,
and PRRs, which regulate IL17 production. TLRs are the well-
studied PRRs expressed by DCs, macrophages, and γδT cells. The
unique microbial molecules called as PAMP are recognized by
TLRs, which orchestrate the anti-microbial response in γδT cells
(11). In malarial infection, MyD88 deficiency results in severe
impairment of IL17A producing γδT cells levels, but not IFNγ
producing γδT cells highlighting differential control by innate
signaling through TLRs in infections (132). Murine Tγδ17 cells
specifically express TLR1 and TLR2 but not TLR4. High num-
ber of Tγδ17 cells were induced upon in vivo stimulation with
Pam3CSK4 (ligand for TLR2) but not with LPS (TLR4 ligand)
or CpG (TLR9 ligand) (70). Interestingly, it has been shown that
TLR4 indirectly controls IL17 generation byγδT cells through IL23
secreted by TLR4 expressing macrophages in response to HMG
Box 1 (HMGB1, a damage-associated protein and TLR4 ligand)
(133). Moreover, Tγδ17 cells promote experimental intraocular
neovascularization (134) as well as early acute allograft rejection
(135) in response to HMGB1. Signaling through TLR2 is indis-
pensable for Tγδ17 in anti-microbial functions. Absence of TLR2
or MyD88 in cutaneous Staphylococcus aureus infection, or in
Candida albicans infection, caused an impaired IL17 production
and poor microbial clearance in the skin infiltrated with Vγ5+
γδT cells (130, 136). Tγδ17 cells also express DC-associated C-
type lectin 1 (dectin 1) and intraperitoneal injection of curdlan
(dictin 1 ligand), induced IL17 production by γδT cells (70). In
imiquimod (IMQ)-induced psoriasis-like model, dermal γδT cells
spontaneously secreted a large amount of IL17 in IMQ-treated
skin cells. Thus, it appears that TLR7/8 (receptor of IMQ) may
regulate the IL17 production by γδT cells. It is important to note
that the modulatory effects of TLRs on γδT cells as showed in
in vivo murine models are mediated through IL23 and/or IL1β
cytokines. The direct stimulation of CD27− γδT cells by TLR lig-
ands (LPS or PAM) show no effect on IL17 production (132). This
suggests that TLR signaling indirectly modulates Tγδ17 function.
RECEPTOR REPERTOIRE EXPRESSED BY Tγδ17 CELLS
The receptor profile of Tγδ17 cells is similar to Th17 cells. In mice,
the majority of IL17-producing CD4 cells belong to CCR6+ com-
partment compared to CCR6− (137). Sorted CCR6+ γδT cells
showed increased mRNA expression of IL17, IL22, IL23R, Rorγt,
and aryl hydrocarbon receptor (AhR) compared to CCR6− γδT
cells (70, 138). This suggests that CCR6 can be a phenotypic surface
marker of Tγδ17 cells. Besides CCR6, Tγδ17 cells express vari-
ous chemokine receptors including CCR1, CCR2, CCR4, CCR5,
CCR7, CCR9, CXCR1, CXCR3, CXCR4, CXCR5, and CXCR6 (7).
The early onset recruitment of Tγδ17 to the site of inflamma-
tion is determined by the type of chemokine receptor on them.
Tγδ17 cells expressing CCR6 and CCR9 show selective migration
toward allergic inflamed tissue in response to CCL25 (ligand for
CCR9). α4β7 integrin expression is indispensable for this migra-
tion and transendothelial crossing of Tγδ17 cells. (139). Since
migration through CCL2/CCR2 axis is determinant for total γδT
cells, CCL25/CCR9-mediated migration seems to be specific for
Tγδ17 subtype (140, 141).
In humans, Tγδ17 cells express CCR6 but not CXCR3, CXCR5,
CCR3, CCR4, or CCR5. However, they express granzyme B, FASL,
and TRAIL but not perforin (66). The lack of granzyme B and
perforin coexpression may be responsible for absence of cytolytic
activity of Tγδ17 cells. On the contrary, it has been shown that the
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human colorectal tumor-infiltrating Tγδ17 cells do not express
FASL or TRAIL but express CD161 and CCR6 (74). The incon-
sistency in expression of cytolytic markers and their relevance on
Tγδ17 cells needs to be understood in detail. The AhR is indispens-
able for Tγδ17 cells as it promotes differentiation of naïve Vγ9Vδ2
T cells toward Tγδ17 phenotype (66).
In mouse model, it has been shown that Ahr−/− Tγδ17 cells
express IL17 but fail to produce IL22 (70). Moreover, in mouse
model of Bacillus subtilis induced pneumonitis, deficiency of Ahr
resulted into low IL22 production but IL17 levels were maintained
(142). Thus, although Ahr promotes IL17, it is indispensable for
IL22 production by Tγδ17 cells.
INFLAMMATORY DISORDERS AND MANIA OF Tγδ17
Th17 cells and Tγδ17cells are essential in disease progression and
are pathogenic in autoimmune disease. Dysregulated levels and
sustained secretion of proinflammatory cytokines by γδ and/or
CD4 T cells have devastating effects on autoimmune disease pro-
gression. In a collagen-induced arthritis (CIA) model (resembling
human rheumatoid arthritis), IL17-producing Vγ4/Vδ4+ T cells
selectively increase in joints and lymph nodes. Depletion of γδ T
cells by anti Vγ4 antibody, markedly reduced the disease sever-
ity score revealing its pathogenic nature (143). Interestingly, both
Th17 and Tγδ17 are present in the joints but Th17 cells local-
ize proximal to the bone, which facilitates its interaction with
osteoclast. Selective depletion of Th17 cells abrogated the bone
resorption suggesting that Th17 but not Tγδ17 cells are respon-
sible for bone destruction. Thus, Tγδ17 cells may be responsible
for enhancing joint inflammation and exacerbate CIA (144). In
contrast, absence of Tγδ17 was reported in patients with rheuma-
toid arthritis and in murine model of autoimmune arthritis (SKG
model) (145). The SKG mouse model has defects in the differenti-
ation of Tγδ17 cells (94), which might result into low Tγδ17 cells
in the inflamed joints. Thus, the role of Tγδ17 cells in autoimmune
arthritis need to be evaluated comprehensively.
Tγδ17 also enhanced experimental autoimmune encephalo-
myelitis (EAE) (mouse model for human multiple sclerosis).
Upon immunization of mice with myelin oligodendrocyte gly-
coprotein (MOG) peptide in complete Freund’s adjuvant (CFA),
Vγ4+CCR6+IL23+ γδT cells accumulate in the central nervous
system (CNS), which expand by 20-fold in absolute number dur-
ing development of clinical signs of the disease (72). In contrast,
IFNγ-producing γδT cells are low in CNS and marginally increase
during course of EAE (103). The mechanism behind aggrava-
tion of EAE could be attributed to restraining the development of
Foxp3+ regulatory T cells (Tregs) functions by Tγδ17 cells. Super-
natants from IL23-activated γδT cells inhibited the TGFβ driven
conversion of naive Foxp3− αβT cells into Foxp3 expressing T cells
and also reversed the suppressive effect of Treg cells (72). Similar
function of Tγδ17 was reported in cardiac transplantation in mice.
IL17, majorly produced by γδT cells, accelerates acute rejection of
transplanted heart but IL17 deficiency enhanced Treg expansion
and prolonged allograft survival (71). In ischemic brain injury,
Tγδ17 were reported to be present at the infract areas (146). Tγδ17
rather than Th17 was the major source of IL17 whereas IFNγ was
majorly produced by Th1 cells. In mice, genetically deficient for
IL17 or IL23, the infract areas were reduced suggesting a role of
Tγδ17 as a key contributor of neuroinflammation (146). Over-
all, this suggests that in chronic inflammatory condition, innate
cytokines IL23 and IL1β promote infiltration and generation of
IL17-producing γδT cells, which aggravate the disease.
Experimental silicosis is a useful model for depicting chronic
lung inflammation, tissue damage, and fibrosis. Tγδ17 along with
Th17 accumulated in the lung in response to IL23 expressing
macrophages by third day after silica treatment but interestingly
did not induce lung fibrosis (73). On the contrary, in allergic
lung inflammation, Tγδ17 cells are known to be protective (147,
148). Functional blockage of both IL17 and γδT cells impaired the
resolution of airway lung inflammation (148). It is claimed that
this protective role is mediated by prostaglandins (PGs), which
are abundant at the site of inflammation. PGI2 analog iloprost
enhanced IL17 production by γδT cells in the thymus, spleen, and
lungs, reducing airway inflammation (147). This highlights the
role of PGI2 analogs that can be exploited in the development of
immune response in immunotherapeutic approaches. Age-related
macular degeneration (AMD) is another chronic inflammation
associated disease, characterized by choroidal neovascularization
(CNV). In an experimental model, Tγδ17 cells along with Thy-1+
ILCs (innate lymphoid cells) infiltrate the eye after laser treatment
and promote neovascularization. This recruitment is in response
to IL1β but not IL23 produced by macrophages (134).
Tγδ17 CELLS AS HEROES OR VILLAINS IN CANCER
The unmatched characteristics of human γδT cells to have
MHC unrestricted tumor directed cytotoxicity, release of copious
amounts of IFNγ, and recognition of cancer cells through vari-
ety of mechanisms render them as potential candidate for cancer
immunotherapy (4, 149). Upon activation, γδT cells show cyto-
toxicity against myeloma (150), lymphoma (151), leukemia (152,
153),and other epithelial carcinomas (57,154,155) in vitro. Several
clinical trials have been launched using γδT cells based therapies
in cancer patients. The hallmark characteristic of γδT cells to be
used for therapy is their ability to infiltrate tumors (156). In vivo
activation by phosphoantigens or adaptive transfer of preactivated
autologous γδT cells have proved successful in cancer treatment
(157). However, the role of Tγδ17 cells as anticancer effector cells
is not well defined.
In a chemotherapeutic approach, Tγδ17 cells are reported to
play decisive role in several transplantable tumor models (EG7 thy-
moma,MCA205 sarcoma,CT26 colon cancer,and TS/A mammary
carcinomas). Tγδ17 (Vγ4+/Vγ6+) cells were shown to invade the
tumor bed early in response after drug treatment. This was fol-
lowed by infiltration and induction of IFNγ-producing CD8 (Tc1)
cells to the tumor bed. This infiltration of Tγδ17 and Tc1 cells
was correlated and associated with tumor regression post radio
or chemotherapy (158). Thus, IL17-producing Vγ4+/Vγ6+ cells
are critical for the induction of Tc1 response in tumor tissue in
response to drug treatment or radiation. Another study in blad-
der cancer supports the helper function of Tγδ17 cells in cancer
treatment. Tγδ17 cells induce neutrophil infiltration to the tumor
site and show anti-tumor effect upon Mycobacterium bovis BCG
treatment (159).
In contrast to anti-tumor role of Tγδ17 cells, they also promote
tumor development. With the notion that IL17 is a proangiogenic
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cytokine (160), Tγδ17 cells promote angiogenesis in tumor model.
In IL17−/− tumor bearing mice, the blood vessel density was
markedly decreased compared to wild type. In addition, IL17
induced the expression of Ang-2 (angiopoietin) and VEGF (vascu-
lar endothelial growth factor) in tumor cells (8). In ovarian cancer
model, it has been reported that CD27− Vγ6+ cells produced
higher IL17 and induce VEGF and Ang-2 in peritoneal exudates of
tumor bearing mice after 6 weeks of post-tumor inoculation (161).
Additionally, Tγδ17 cells induce mobilization of protumor small
peritoneal macrophages (SPM) to the tumor bed, which express
IL17-dependent proangiogenic profile (Il1b, Il6, vegfa, tgfb, mif,
cxcl1, cxcl8, and tie2). SPMs also enhance ovarian cancer growth
by stimulating tumor cell proliferation (161). In hepatocellular
carcinoma mouse model, it was reported that IL17, majorly pro-
duced by Vγ4+γδT cells, induced CXCL5 production by tumor
cells, which enhance migration of MDSCs (myeloid-derived sup-
pressor cells) expressing CXCR2 to the tumor site. In addition,
IL17 also enhanced suppressive functions of MDSCs by inhibition
of T cells proliferation and cytokine (IFNγ and TNFα) produc-
tion (162). In return, MDSCs induced γδT cells to produce IL17
through IL23 and IL1β secretion forming positive feedback loop
for Tγδ17 activation (162). Thus, Tγδ17 cells interact with myeloid
cells and counteract tumor immune-surveillance.
In human colorectal cancer, IL8 and GM-CSF secreted by Tγδ17
promote migration of MDSCs while IL17 and GM-CSF enhanced
their proliferation. Tγδ17 cells also support survival of MDSCs
through IL17, IL8, and TNFα (74). Thus, it is possible to specu-
late that Tγδ17 cells might be responsible for gradual shift from
initial inflammatory to immunosuppressive tumor environment
in advanced stage cancer (163). In human colorectal carcinoma,
Tγδ17 cells were positively correlated with advancing tumor stages
as well as with clinicopathological features including tumor size,
tumor invasion, lymphatic and vascular invasion, lymph node
metastasis, and serum CEA (Carcinoembryonic antigen) levels
suggesting their pathogenic role (74).
Collectively, these findings highlight the apparently opposite
roles of Tγδ17 cells in cancer immunity. It seems that during tumor
development, inflammatory environment (IL1β and IL23) mod-
ulate the cytokine profile of γδT cells from primary IFNγ toward
proinflammatory IL17, which support tumor progression.
CONCLUDING REMARKS
Despite the small percentage in total T cell population, γδT
cells have emerged as an important modulator of early immune
responses. The development of functional subtypes of γδT
cells require polarizing cues including molecular and cellular
FIGURE 2 | Functions ofTγδ17 cells in pathological conditions.
(A) Tγδ17 cells promote infiltration of neutrophils and monocytes/
macrophages to the site of inflammation through chemokines. (B) IL17
secreted by Tγδ17 cells induces keratinocytes to produce anti-microbial
peptides such as β defensins and protect host in infections.
(C) Dysregulated Tγδ17 cells in autoimmune diseases inhibit Treg
expansion and its ability to suppress autoreactive cell, thereby
exacerbating the disease. (D) The inflammatory condition in arthritis is
worsened by IL17, which foster osteoclast formation through induction of
RANKL. Tγδ17 cells are involved in bone resorption and enhance joint
inflammation. (E) Human Tγδ17 cells support MDSC migration, survival,
and promote their suppressive functions through IL17, GMCSF, and IL8.
MDSCs also form feedback loop and promote Tγδ17 differentiation through
IL23 and IL1β. (F) Tγδ17 cells secrete IL17 and induce tumorigenesis by
their proangiogenic activity. (G) Murine Tγδ17 cells recruit small peritoneal
macrophages to the tumor bed, which induce angiogenesis.
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interaction and combination of multiple cytokines and chemokine
receptors that regulate their distribution. This suggests that the
functional determination of γδT cell subtypes is dictated by the
local environment (thymus or peripheral blood or the inflamed
tissue) in which they are present. Tγδ17 is a special γδT cell sub-
set, distinctly present at early immune response in the tissue and
can modulate the functions of other immune and epithelial cells
but their relevance in disease outcome remains controversial. In
response to microbial antigens, Tγδ17 cells promote infiltration
of neutrophils and macrophages and induce production of anti-
microbial peptides resulting in clearance of microbial load. Such
protective behavior of Tγδ17 cells in infections can be exploited
to develop newer approaches to tackle the microbial pathology
(Figure 2).
The opposite side of Tγδ17 functions has revealed its detri-
mental role in enhancing inflammation in autoimmunity and
cancer (Figure 2). The mechanism, which regulates such dual
personality of Tγδ17 cells is unknown. It appears that the obvi-
ous common role executed by these cells is enhancement of
inflammation but due to functional heterogeneity and their com-
plex interdependency on other cells (innate and adaptive); the
emerging scenario of their biology is far from complete. This pro-
vokes us to consider contextual behavior of Tγδ17 cells in disease
pathology. Current progress in understanding the significance of
Tγδ17 cells in inflammatory diseases has revealed their novel but
debilitating functions such as suppression of Tregs in autoimmu-
nity, induction of angiogenesis, and recruitment and activation
of MDSCs in various malignancies. Thus, in inflammatory dis-
orders, Tγδ17 cells can be targeted using various immunother-
apeutic approaches. However, need of hour is to expand the
understandings of Tγδ17 in humans and develop a protocol for
their propagation and activation. The future therapies will rely
on regulating the key transcription factor RORγt by designing
suitable antagonists that will help in fine tuning Tγδ17 differ-
entiation and eventually their function in chronic inflammation
and infection.
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